Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a strategic collaboration with Elligo Health Research. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone919-876-9300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.67 billion
Profitability
Miscellaneous
Employees21,000
OptionableOptionable
Syneos Health (NASDAQ:SYNH) Frequently Asked Questions
What is Syneos Health's stock symbol?
Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."
How were Syneos Health's earnings last quarter?
Syneos Health Inc (NASDAQ:SYNH) posted its quarterly earnings data on Tuesday, November, 6th. The company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.17. The firm had revenue of $1.11 billion for the quarter, compared to analysts' expectations of $1.12 billion. Syneos Health had a positive return on equity of 8.67% and a negative net margin of 0.84%. The business's revenue was up 88.3% compared to the same quarter last year. View Syneos Health's Earnings History.
When is Syneos Health's next earnings date?
What guidance has Syneos Health issued on next quarter's earnings?
Syneos Health updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of $2.66-2.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.70. The company issued revenue guidance of $4.375-4.435 billion, compared to the consensus revenue estimate of $4.45 billion.Syneos Health also updated its FY 2018 guidance to EPS.
What price target have analysts set for SYNH?
10 analysts have issued 1-year price objectives for Syneos Health's shares. Their forecasts range from $45.00 to $60.00. On average, they expect Syneos Health's share price to reach $54.75 in the next twelve months. This suggests a possible upside of 12.6% from the stock's current price. View Analyst Price Targets for Syneos Health.
What is the consensus analysts' recommendation for Syneos Health?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.
Has Syneos Health been receiving favorable news coverage?
Media coverage about SYNH stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syneos Health earned a news impact score of 0.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
Who are some of Syneos Health's key competitors?
Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), BTG (BTGGF), Medpace (MEDP), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL), Senomyx (SNMX) and Dyadic International (DYAI).
Who are Syneos Health's key executives?
Syneos Health's management team includes the folowing people:
- Mr. Alistair MacDonald, CEO & Director (Age 48)
- Dr. Michael Gibertini, Pres of Clinical Devel. for Therapeutic Bus. Units (Age 60)
- Mr. Michael Adam Bell, Consultant (Age 62)
- Mr. Jason M. Meggs, Chief Financial Officer (Age 42)
- Dr. Judith Ng-Cashin, Chief Scientific Officer
Who are Syneos Health's major shareholders?
Syneos Health's stock is owned by many different of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.64%), Retirement Systems of Alabama (0.26%), Boston Advisors LLC (0.05%), Louisiana State Employees Retirement System (0.02%), National Investment Services Inc. WI (0.01%) and First Hawaiian Bank (0.01%). Company insiders that own Syneos Health stock include Alistair Macdonald, Christopher L Gaenzle, Gregory S Rush, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.
Which institutional investors are selling Syneos Health stock?
SYNH stock was sold by a variety of institutional investors in the last quarter, including National Investment Services Inc. WI, Peregrine Capital Management LLC and Louisiana State Employees Retirement System. Company insiders that have sold Syneos Health company stock in the last year include Christopher L Gaenzle and H Lee Equity Fund Vi Thomas. View Insider Buying and Selling for Syneos Health.
Which institutional investors are buying Syneos Health stock?
SYNH stock was acquired by a variety of institutional investors in the last quarter, including Boston Advisors LLC, Virtu Financial LLC, Meeder Asset Management Inc., Retirement Systems of Alabama and First Hawaiian Bank. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.
How do I buy shares of Syneos Health?
Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syneos Health's stock price today?
One share of SYNH stock can currently be purchased for approximately $48.61.
How big of a company is Syneos Health?
Syneos Health has a market capitalization of $4.94 billion and generates $2.67 billion in revenue each year. The company earns $-138,460,000.00 in net income (profit) each year or $1.94 on an earnings per share basis. Syneos Health employs 21,000 workers across the globe.
What is Syneos Health's official website?
How can I contact Syneos Health?
Syneos Health's mailing address is 3201 Beechleaf Court Suite 600, Raleigh NC, 27604. The company can be reached via phone at 919-876-9300 or via email at [email protected]
MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
